Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jin, Xia, Ramanathan, Jr., Murugappan, Barsoum, Shady, Deschenes, Geoffrey R., Ba, Lei, Binley, James, Schiller, Daryl, Bauer, Daniel E., Chen, Donald C., Hurley, Arlene, Gebuhrer, Lucette, El Habib, Raphaelle, Caudrelier, Pierre, Klein, Michel, Zhang, Linqi, Ho, David D., Markowitz, Martin
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2002
Schlagworte:
Vaccines and Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC135946/
https://ncbi.nlm.nih.gov/pubmed/11836398
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge